Immunological and clinical consequences of treating a patient with natalizumab.
about
Progressive multifocal leukoencephalopathy: current treatment options and future perspectivesDrug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.Immune reconstitution inflammatory syndrome in a patient with progressive multifocal leukoencephalopathy.Current approaches to the management of new-onset ulcerative colitis.Immunological Markers for PML Prediction in MS Patients Treated with NatalizumabJC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis.Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.Natalizumab-associated progressive multifocal leukoencephalopathy in a patient with multiple sclerosis: a postmortem study.Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome.Central nervous system immune reconstitution inflammatory syndrome.Medications and therapeutic apheresis procedures: are we doing our best?Therapeutic uses of anti-α4-integrin (anti-VLA-4) antibodies in multiple sclerosis.Immune reconstitution inflammatory syndrome associated with biologic therapy.Progressive multifocal leukoencephalopathy and immune reconstitution inflammatory syndrome (IRIS).Fingolimod treatment promotes regulatory phenotype and function of B cells.Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc.VLA-4 blockade promotes differential routes into human CNS involving PSGL-1 rolling of T cells and MCAM-adhesion of TH17 cells.The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity.Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients.
P2860
Q26776236-2FAD4C73-E3ED-487E-A776-6E93C02A0A43Q30815289-CFB02BB8-5DEF-46CB-9E33-0CF18B74CC14Q30969485-7CDE93E0-4F58-4091-A25D-AECA6EFD79CEQ33633288-236755D9-8771-45C7-A3ED-582C16DC284CQ34818048-4B10F952-2B59-4DD5-BA54-15D68E74FA61Q35586120-F1B0DC4A-82B9-4A6D-9952-3A1BB5ABE5C1Q35671182-A6A277BD-3261-49F0-85DD-A817E1900DC9Q35675602-10D482F6-0C4A-4748-A846-44A9BAA8E1B0Q35736438-144DA7A0-6FEC-46C4-9AEA-12BEBC301FABQ37313729-8B048062-ACF0-417B-8C96-F96E065B07D6Q37442512-815860EF-8AC1-4219-81C7-789B9807AA8BQ38082738-8451A1BE-EF50-46FA-AE0F-86851F18D280Q38261176-9CE27030-5A9F-408F-8A60-800C1627724DQ38287572-C130A985-6579-4992-A07D-B31A0A774A2EQ38577593-5129DC4C-A56C-4678-A779-1EE06E8B3B5FQ41268957-8452D405-D5EB-446A-A0BA-C5AEFFED7365Q41860847-213D6D5C-CD16-4E8E-B4D0-4844C6059FE4Q41966039-ACCE738A-436C-41F6-95AB-AB5968A4123DQ47114458-28E7450F-3ECC-4D2F-B1A4-324820A4E590Q54207057-025085FE-8463-4778-A0A4-ABBD373D1189
P2860
Immunological and clinical consequences of treating a patient with natalizumab.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Immunological and clinical consequences of treating a patient with natalizumab.
@en
Immunological and clinical consequences of treating a patient with natalizumab.
@nl
type
label
Immunological and clinical consequences of treating a patient with natalizumab.
@en
Immunological and clinical consequences of treating a patient with natalizumab.
@nl
prefLabel
Immunological and clinical consequences of treating a patient with natalizumab.
@en
Immunological and clinical consequences of treating a patient with natalizumab.
@nl
P2093
P2860
P50
P356
P1476
Immunological and clinical consequences of treating a patient with natalizumab.
@en
P2093
Karin G Höhn
Max-Philipp Stenner
Richard M Ransohoff
Samantha Jilek
Sven G Meuth
Tilman Schneider-Hohendorf
Wolfgang Brück
P2860
P304
P356
10.1177/1352458511421919
P577
2011-09-09T00:00:00Z